Please login to the form below

Not currently logged in
Email:
Password:

NHS Commissioning Board

This page shows the latest NHS Commissioning Board news and features for those working in and with pharma, biotech and healthcare.

UK relaunches lung cancer campaign

UK relaunches lung cancer campaign

Be Clear On Cancer was designed and executed by Public Health England (PHE), in partnership with the Department of Health (DH) and the NHS Commissioning Board. ... National clinical director for cancer at NHS England, Sean Duffy, said: “ Awareness

Latest news

  • David Nicholson to step down as head of England’s NHS David Nicholson to step down as head of England’s NHS

    Sir David Nicholson has said he will leave his position as chief executive of NHS England in March 2014. ... Sir David has been in the role since the organisation was formed at the NHS Commissioning Board in 2012 as part of a series of major healthcare

  • Charity says patients worried about Cancer Drugs Fund's future Charity says patients worried about Cancer Drugs Fund's future

    The CDF was set up in 2011 as a temporary measure to provide financing for drugs not available for mainstream NHS use because they had not been recommended by the National ... of the Fund, but added that responsibility for it was likely to fall to the

  • Clarity still needed on VBP as NICE adds social care to remit Clarity still needed on VBP as NICE adds social care to remit

    existing responsibilities to provide healthcare guidelines and assess whether a new drug or technology is a cost-effective use of NHS resources. ... for when it closes in 2014, although Prof Leng said that these medicines are likely to fall under the

  • Quality Standards – are we making the most of them? Quality Standards – are we making the most of them?

    In theory it is the NHS Commissioning Board's CCG Outcomes Indicator Set that will incentivise commissioners to match Quality Standards, so it is the ability of these indicators to measure ... the contents of the Quality Standards that will be key to

  • Is the new NHS guidance relevant to pharma? Is the new NHS guidance relevant to pharma?

    Is the new NHS guidance relevant to pharma? The new NHS Commissioning Board has published its most important document of the year - one that will have a huge impact on the ... The planning guidance, together with the NHS Outcomes Framework, is the

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • England’s clinical commissioning landscape England’s clinical commissioning landscape

    England’ s clinical commissioning landscape. Who are the real masters in the new NHS? ... The 211 CCGs are monitored by, and co-commission services with, NHS England (formerly known as the NHS Commissioning Board).

  • Outcomes shape the new European payer networks Outcomes shape the new European payer networks

    The key components of the new NHS structure for England are made up of NICE, the new NHS Commissioning Board and its substructure, including the new Clinical Commissioning Groups (CCGs), who ... The new NHS Commissioning Board is focused on addressing

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    Primary Care Trusts and Strategic Health Authorities are no more – replaced by the mix of Clinical Commissioning Groups (CCGs) and NHS England (formerly the NHS Commissioning Board) – while several groups, including ... Ready for the challenge. Prof

  • Revamping the NHS and the challenges for pharma Revamping the NHS and the challenges for pharma

    The NHS National Commissioning Board, recently renamed as NHS England, was set up as an independent regulatory body to oversee the authorisation process for CCGs and to improve health outcomes for ... The NHS Commissioning Board will work closely with

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Prof Sir Mike Richards joins Incisive Health as senior counsel Prof Sir Mike Richards joins Incisive Health as senior counsel

    In July 2012 he was appointed as Director for Reducing Premature Mortality on the NHS Commissioning Board (now NHS England), where he led the development of a cardiovascular outcomes strategy. ... These are vital attributes if the NHS is to navigate the

  • New NHS CEO announces senior changes New NHS CEO announces senior changes

    New NHS CEO announces senior changes. Simon Stevens strengthens leadership within NHS England. ... Further appointments to this programme will be announced in time. Elsewhere, Ian Dodge was appointed to the NHS England board as national director for

  • Ian Dalton leaves NHS to lead health services at BT Ian Dalton leaves NHS to lead health services at BT

    The NHS Commissioning Board's chief operating officer and deputy chief executive Ian Dalton has left to join telecommunications firm BT as president of global health. ... For the next period, my focus will be on delivering what I am sure will be a

  • NHS confirms departure of Jim Easton to Care UK NHS confirms departure of Jim Easton to Care UK

    It had previously been rumoured that Easton, national director of transformation at the NHS Commissioning Board and national director for improvement and efficiency at the Department of Health, would leave his ... In recent months I have also had the

  • NHS’ Jim Easton reportedly joining Care UK NHS’ Jim Easton reportedly joining Care UK

    NHS’ Jim Easton reportedly joining Care UK. HSJ says he has resigned as director of transformation at NHS Commissioning Board. ... He joined the NHS Commissioning Board following its creation to oversee regional clinical commissioning groups and

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics